000661 长春高新
已收盘 08-17 15:00:00
资讯
新帖
简况
股市必读:长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》
证券之星 · 08-14
股市必读:长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》
长春高新(000661)披露2026年限制性股票激励计划激励对象名单审核及公示情况说明,8月12日股价下跌0.71%
证券之星 · 08-12
长春高新(000661)披露2026年限制性股票激励计划激励对象名单审核及公示情况说明,8月12日股价下跌0.71%
长春高新(000661)披露子公司GenSci148注射液临床试验申请获批公告,8月10日股价上涨3.09%
证券之星 · 08-10
长春高新(000661)披露子公司GenSci148注射液临床试验申请获批公告,8月10日股价上涨3.09%
长春高新董秘李洪谕荣获第十二届金麒麟·金牌董秘荣誉
新浪财经 · 08-10
长春高新董秘李洪谕荣获第十二届金麒麟·金牌董秘荣誉
长春高新:公司以经营业绩为市值管理根本
证券之星 · 08-07
长春高新:公司以经营业绩为市值管理根本
半价“金手铐”定向激励背后:金赛药业三年净利蒸发40亿元,长春高新跌落千亿市值神坛
证券之星 · 08-06
半价“金手铐”定向激励背后:金赛药业三年净利蒸发40亿元,长春高新跌落千亿市值神坛
长春高新最新公告:子公司GenSci133注射液临床试验申请获受理
证券之星 · 08-05
长春高新最新公告:子公司GenSci133注射液临床试验申请获受理
股市必读:长春高新新发布《关于子公司GenSci144片境内生产药品注册临床试验申请获得批准的公告》
证券之星 · 08-03
股市必读:长春高新新发布《关于子公司GenSci144片境内生产药品注册临床试验申请获得批准的公告》
长春高新(000661)披露子公司GenSci144片境内临床试验申请获批公告,7月30日股价下跌0.81%
证券之星 · 07-30
长春高新(000661)披露子公司GenSci144片境内临床试验申请获批公告,7月30日股价下跌0.81%
长春高新最新公告:子公司GenSci144片临床试验申请获批准
证券之星 · 07-30
长春高新最新公告:子公司GenSci144片临床试验申请获批准
7月27日长春高新涨5.82%,生物医药ETF国泰基金重仓该股
证券之星 · 07-27
7月27日长春高新涨5.82%,生物医药ETF国泰基金重仓该股
长春高新最新公告:子公司注射用GenSci136临床试验申请获受理
证券之星 · 07-23
长春高新最新公告:子公司注射用GenSci136临床试验申请获受理
长春高新(000661)披露2026年限制性股票激励计划管理办法,7月22日股价上涨3.01%
证券之星 · 07-22
长春高新(000661)披露2026年限制性股票激励计划管理办法,7月22日股价上涨3.01%
7月16日长春高新涨5.40%,创新药ETF银华基金重仓该股
证券之星 · 07-16
7月16日长春高新涨5.40%,创新药ETF银华基金重仓该股
长春高新:预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元
证券之星 · 07-14
长春高新:预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元
长春高新最新公告:预计2026年半年度净利润同比下降40%-60%
证券之星 · 07-14
长春高新最新公告:预计2026年半年度净利润同比下降40%-60%
长春高新最新公告:子公司产品银花泌炎灵片新纳入国家基本药物目录
证券之星 · 07-10
长春高新最新公告:子公司产品银花泌炎灵片新纳入国家基本药物目录
7月10日长春高新涨5.48%,创新药ETF银华基金重仓该股
证券之星 · 07-10
7月10日长春高新涨5.48%,创新药ETF银华基金重仓该股
长春高新:以经营业绩为市值管理根本
证券之星 · 07-10
长春高新:以经营业绩为市值管理根本
长春高新(000661)披露子公司GenSci148注射液临床试验申请获受理公告,7月8日股价下跌0.91%
证券之星 · 07-08
长春高新(000661)披露子公司GenSci148注射液临床试验申请获受理公告,7月8日股价下跌0.91%
加载更多
公司概况
公司名称:
长春高新技术产业(集团)股份有限公司
所属行业:
医药制造业
上市日期:
1996-12-18
主营业务:
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。
发行价格:
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":84.53,"timestamp":1786950183000,"preClose":84.59,"halted":0,"volume":6380616,"delay":0,"changeRate":-0.0007,"floatShares":400000000,"shares":408000000,"eps":-0.103,"marketStatus":"已收盘","change":-0.06,"latestTime":"08-17 15:00:00","open":84.35,"high":85.86,"low":83.28,"amount":539000000,"amplitude":0.0305,"askPrice":84.54,"askSize":2,"bidPrice":84.53,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-0.103,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787016600000},"marketStatusCode":5,"adr":0,"adjPreClose":84.59,"symbolType":"stock","openAndCloseTimeList":[[1786930200000,1786937400000],[1786942800000,1786950000000]],"highLimit":93.05,"lowLimit":76.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.55,"roa":"--","roe":"1.25%","epsLYR":0.39,"committee":0.675214,"marketValue":34483000000,"turnoverRate":0.016,"status":1,"floatMarketCap":33779000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2659916962","title":"股市必读:长春高新新发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659916962","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659916962?lang=zh_cn&edition=full","pubTime":"2026-08-14 00:57","pubTimestamp":1786640229,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘,长春高新报收于85.45元,下跌0.85%,换手率2.52%,成交量10.07万手,成交额8.7亿元。当日关注点交易信息汇总:8月13日主力资金净流出1750.86万元,占总成交额2.01%。公司公告汇总:2026年限制性股票激励计划激励对象名单公示期结束,未收到异议;董事会薪酬与考核委员会确认激励对象主体资格合法有效,且不包括董事、高管、总部及控股子公司人员,亦不含持股5%以上股东及其亲属。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0075","BK0046","BK0057","BK0188","000661","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903944","title":"长春高新(000661)披露2026年限制性股票激励计划激励对象名单审核及公示情况说明,8月12日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903944?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:05","pubTimestamp":1786543520,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘,长春高新报收于86.18元,较前一交易日下跌0.71%,最新总市值为351.56亿元。该股当日开盘86.78元,最高88.58元,最低86.0元,成交额达9.7亿元,换手率为2.79%。近日,长春高新技术产业(集团)股份有限公司披露《董事会薪酬与考核委员会关于2026年限制性股票激励计划激励对象名单的审核及公示情况说明》。激励对象主体资格合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200039938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0075","BK0188","BK0046","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658932501","title":"长春高新(000661)披露子公司GenSci148注射液临床试验申请获批公告,8月10日股价上涨3.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658932501","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658932501?lang=zh_cn&edition=full","pubTime":"2026-08-10 22:14","pubTimestamp":1786371256,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘,长春高新报收于83.0元,较前一交易日上涨3.09%,最新总市值为338.59亿元。该股当日开盘80.9元,最高83.73元,最低80.5元,成交额达11.06亿元,换手率为3.35%。近日,长春高新技术产业(集团)股份有限公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,GenSci148注射液境内生产药品注册临床试验申请获得批准。临床试验后续进程及结果存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000033912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0075","BK0028","BK0057","000661","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658985916","title":"长春高新董秘李洪谕荣获第十二届金麒麟·金牌董秘荣誉","url":"https://stock-news.laohu8.com/highlight/detail?id=2658985916","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658985916?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:27","pubTimestamp":1786346820,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索查看更多考评等级专题:专题:第十二届金麒麟·金牌董秘及优秀证代荣誉榜单揭晓!8月10日,新浪财经第十二届金麒麟金牌董秘榜单正式揭晓。长春高新董事会秘书李洪谕凭借扎实的合规治理能力、成熟的投资者关系运营、长期稳健的资本价值传递表现,荣耀加冕第十二届金麒麟金牌董秘。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2026-08-10/doc-inimvhfr4982251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0057","BK0188","000661","BK0046","BK0028","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657194566","title":"长春高新:公司以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2657194566","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657194566?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:18","pubTimestamp":1786094289,"startTime":"0","endTime":"0","summary":"公司管理层高度重视市值管理工作,但二级市场股价受宏观环境、行业周期、市场情绪等多重因素影响。公司未来若有达到信息披露要求的市值管理相关举措安排,将严格履行决策程序并及时对外披露,谢谢!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700029226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0046","BK0239","BK0075","BK0028","000661","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657505289","title":"半价“金手铐”定向激励背后:金赛药业三年净利蒸发40亿元,长春高新跌落千亿市值神坛","url":"https://stock-news.laohu8.com/highlight/detail?id=2657505289","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657505289?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:08","pubTimestamp":1785985713,"startTime":"0","endTime":"0","summary":"证券之星注意到,金赛药业作为贡献八成以上营收的“利润奶牛”,近年来业绩急剧失速——归属净利润从2023年的45.14亿元“断崖式”跌至2025年的4.87亿元,直接拖累长春高新2025年归属净利润骤降94%至1.55亿元。2025年,金赛药业营业收入占长春高新营业收入比重约为81.3%。除了金赛药业外,长春高新旗下其余业务板块同样表现不佳。2026年6月12日,长春高新被正式调整出沪深300指数样本股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026080600013975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0075","BK0028","BK0057","000661","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657517472","title":"长春高新最新公告:子公司GenSci133注射液临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657517472","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657517472?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:42","pubTimestamp":1785922946,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司控股子公司金赛药业收到国家药监局核准签发的《受理通知书》,GenSci133注射液境内生产药品注册临床试验申请获得受理。该药品为自主研发的PTH多肽与抗RANKL抗体融合蛋白,属于治疗用生物制品1类,拟用于治疗骨质疏松症,旨在通过抑制骨吸收和促进骨形成实现骨量净增加,预期每3-6个月皮下注射1次。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500032228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","BK0057","BK0046","000661","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656348914","title":"股市必读:长春高新新发布《关于子公司GenSci144片境内生产药品注册临床试验申请获得批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656348914","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656348914?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:18","pubTimestamp":1785691090,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,长春高新报收于81.0元,上涨0.63%,换手率2.21%,成交量8.82万手,成交额7.18亿元。公司公告汇总:子公司金赛药业自主研发的GenSci144片获国家药监局批准开展境内临床试验,拟用于慢性肾脏病治疗。GenSci144片为金赛药业自主研发的化药1类口服小分子抑制剂,作用机制与现有药物不同,可望与现有疗法联用。该药此前已获批用于苯丙酮尿症的临床试验。临床试验后续进程与结果存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0028","BK0046","BK0239","BK0057","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655780543","title":"长春高新(000661)披露子公司GenSci144片境内临床试验申请获批公告,7月30日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655780543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655780543?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:15","pubTimestamp":1785420919,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘,长春高新报收于80.49元,较前一交易日下跌0.81%,最新总市值为328.35亿元。近日,长春高新技术产业(集团)股份有限公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,GenSci144片境内生产药品注册临床试验申请获得批准,拟用于慢性肾脏病治疗。该药此前已获批用于苯丙酮尿症的临床试验。临床试验后续进程与结果存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000039583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0188","BK0028","BK0075","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655820328","title":"长春高新最新公告:子公司GenSci144片临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655820328","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655820328?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:47","pubTimestamp":1785404829,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司子公司金赛药业收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,GenSci144片境内生产药品注册临床试验申请获得批准,拟用于慢性肾脏病的治疗。该药品为靶向SLC6A19的口服小分子抑制剂,作用机制与现有药物不同,预期可适用于全类型CKD患者。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000027907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0188","BK0028","BK0075","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654301349","title":"7月27日长春高新涨5.82%,生物医药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654301349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654301349?lang=zh_cn&edition=full","pubTime":"2026-07-27 16:44","pubTimestamp":1785141858,"startTime":"0","endTime":"0","summary":"证券之星消息,7月27日长春高新涨5.82%,收盘报79.8元,换手率2.76%,成交量11.02万手,成交额8.68亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共13家,其中持有数量最多的公募基金为国泰基金的生物医药ETF国泰。生物医药ETF国泰目前规模为37.03亿元,最新净值0.9923,较上一交易日下跌3.17%,近一年下跌8.08%。生物医药ETF国泰的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700021030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0075","BK0028","512290","BK0239","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653745382","title":"长春高新最新公告:子公司注射用GenSci136临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2653745382","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653745382?lang=zh_cn&edition=full","pubTime":"2026-07-23 17:49","pubTimestamp":1784800164,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司控股子公司金赛药业收到国家药监局核准签发的《受理通知书》,注射用GenSci136的境内生产药品注册临床试验申请获得受理,拟用于治疗系统性红斑狼疮(SLE)。该药品为金赛药业自主研发的治疗用生物制品1类药物,采用全新分子结构和BAFF/APRIL双靶点作用机制,有望为SLE患者提供新的治疗选择。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300036389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0239","BK0028","000661","BK0046","BK0057","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653654897","title":"长春高新(000661)披露2026年限制性股票激励计划管理办法,7月22日股价上涨3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653654897","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653654897?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:04","pubTimestamp":1784729058,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘,长春高新报收于77.44元,较前一交易日上涨3.01%,最新总市值为315.91亿元。该股当日开盘75.18元,最高77.89元,最低74.28元,成交额达10.48亿元,换手率为3.44%。近日,长春高新技术产业(集团)股份有限公司披露《2026年限制性股票激励计划管理办法》。公告显示,该办法明确激励计划的管理机构、实施程序、特殊情形处理、信息披露及财务税收规定等内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0075","BK0046","BK0057","000661","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651412042","title":"7月16日长春高新涨5.40%,创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651412042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651412042?lang=zh_cn&edition=full","pubTime":"2026-07-16 16:25","pubTimestamp":1784190337,"startTime":"0","endTime":"0","summary":"证券之星消息,7月16日长春高新涨5.40%,收盘报75.94元,换手率4.54%,成交量18.13万手,成交额13.45亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600026178.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159316","BK0057","BK0188","BK0239","000661","BK0046","BK0028","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651846105","title":"长春高新:预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651846105","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651846105?lang=zh_cn&edition=full","pubTime":"2026-07-14 20:12","pubTimestamp":1784031174,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新发布业绩预告,预计2026年1-6月归属净利润盈利3.93亿元至5.9亿元。长春高新2026年一季报显示,一季度公司主营收入25.87亿元,同比下降13.69%;归母净利润2.76亿元,同比下降41.67%;扣非净利润2.82亿元,同比下降42.61%;负债率18.3%,投资收益-2782.4万元,财务费用901.48万元,毛利率77.95%。本文数据来源于《长春高新:2026年半年度业绩预告》,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400044486.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651177581","title":"长春高新最新公告:预计2026年半年度净利润同比下降40%-60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651177581","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651177581?lang=zh_cn&edition=full","pubTime":"2026-07-14 18:50","pubTimestamp":1784026219,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,预计2026年半年度归属于上市公司股东的净利润为3.93亿元-5.90亿元,同比下降40%-60%。业绩变动主要系新版国家医保目录实施后,公司长效生长激素等产品价格大幅下降,导致营业收入及净利润减少。注:公司Q2净利润预计1.17亿-3.14亿,Q1净利润2.76亿,据此计算,Q2净利润预计环比变动-57%-13%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400039575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650186094","title":"长春高新最新公告:子公司产品银花泌炎灵片新纳入国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2650186094","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650186094?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:30","pubTimestamp":1783675853,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称,公司控股子公司吉林华康药业股份有限公司的银花泌炎灵片新纳入《国家基本药物目录(2026年版)》,该目录自2026年9月1日起施行。该产品本次新纳入目录对其后续扩大市场覆盖及产品销售将产生积极作用,但短期内对公司业绩不会产生重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。相关 ETF","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031840.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0239","BK0046","BK0188","BK0028","BK0057","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183905","title":"7月10日长春高新涨5.48%,创新药ETF银华基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650183905?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:27","pubTimestamp":1783672079,"startTime":"0","endTime":"0","summary":"证券之星消息,7月10日长春高新涨5.48%,收盘报69.5元,换手率3.69%,成交量14.76万手,成交额10.16亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共29家,其中持有数量最多的公募基金为银华基金的创新药ETF银华。创新药ETF银华的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","159316","BK0075","BK0188","BK0046","BK0057","000661","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650269188","title":"长春高新:以经营业绩为市值管理根本","url":"https://stock-news.laohu8.com/highlight/detail?id=2650269188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650269188?lang=zh_cn&edition=full","pubTime":"2026-07-10 15:54","pubTimestamp":1783670059,"startTime":"0","endTime":"0","summary":"证券之星消息,长春高新(000661)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问:请问一下公司跟跌不跟涨的原因是什么,最近公司有什么大雷还是什么原因。面对公司最近股票的走势,请问公司的应对方法是什么?长春高新回复:感谢您对公司的关注和建议。公司以经营业绩为市值管理根本,一直在努力提升经营质量,加快产品研发、销售力度,筑牢内在价值根基;也将在合规的基础上持续提升资本市场沟通力度,多措并举推动市值真实匹配企业内在价值,提振长期持股信心。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。相关 ETF责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000026328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0028","BK0057","BK0046","BK0188","BK0239","BK0075"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649008991","title":"长春高新(000661)披露子公司GenSci148注射液临床试验申请获受理公告,7月8日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649008991","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649008991?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:16","pubTimestamp":1783520183,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,长春高新报收于65.46元,较前一交易日下跌0.91%,最新总市值为267.04亿元。该股当日开盘66.1元,最高67.56元,最低65.31元,成交额达4.33亿元,换手率为1.63%。近日,长春高新子公司金赛药业收到国家药品监督管理局签发的《受理通知书》,其自主研发的GenSci148注射液境内生产药品注册临床试验申请已获受理。该事项符合公司在眼科领域的战略规划,但后续研发进程及结果存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0057","BK0239","BK0188","BK0028","BK0075","000661","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786991323474,"stockEarnings":[{"period":"1week","weight":0.0184},{"period":"1month","weight":0.1663},{"period":"3month","weight":0.0158},{"period":"6month","weight":-0.0307},{"period":"1year","weight":-0.1707},{"period":"ytd","weight":-0.0848}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.058},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.0244},{"period":"1year","weight":0.0773},{"period":"ytd","weight":0.0035}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"138133人(较上一季度增加7.70%)","perCapita":"2892股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售。公司的主要产品是注射用人生长激素、重组人生长激素注射液、注射用重组人促卵泡激素、重组人促卵泡激素注射液、醋酸曲普瑞林注射液、伏欣奇拜单抗、屋尘螨变应原制剂、醋酸甲地孕酮口服混悬液、口腔凝胶、水痘减毒活疫苗、带状疱疹减毒活疫苗、冻干鼻喷流感减毒活疫苗、鼻喷流感减毒活疫苗、银花泌炎灵片、清胃止痛微丸、血栓心脉宁片、疏清颗粒。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}